COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04606407

Asher Tal

Not reported

2020-10-28

Completed

RCT

Randomized

Parallel

Open label

multi-center

Treatment

inclusion criteria: patients (male and female) admitted to the hospital for clinical diagnosis of viral pneumonia including covid-19 patients that have a positive nasal swab. age 18 to 80 years female subjects must be willing to use medically acceptable contraception from screening to day 30 (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent). ability to understand and comply with study requirements. signed informed consent by subject

patients with pneumonia with two or more of the following: wbc of more than 15,000 lobar pneumonia pleural effusion patients who are treated with or require high flow nasal cannula, cpap, intubation, mechanical ventilation, or tracheostomy breastfeeding or pregnancy as evidenced by a positive pregnancy test. subjects diagnosed with immunodeficiency, with history of congestive or unstable heart disease, left ventricular dysfunction (lvef <40%) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension use of an investigational drug during the last 30 days prior enrollment methemoglobin level >3% at screening patients on chronic (over two weeks of treatment) systemic steroids (any formulation, excluding dexamethasone or prednisone) within 30 days prior to enrollment. history of daily, continuous oxygen supplementation patients with bmi greater than or equal to 40 patients with clinically significant anemia, e.g., hb <10.0 and/or thrombocytopenia, e.g., platelets <75. smokers who are unwilling to refrain from smoking during hospitalization presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the subject or the quality of the data, e.g., known or suspected thalassemia, sickle cell disease or other diseases associated with poor oxygen carrying capacity. the subject is identified by the investigator as being unable or unwilling to perform study procedures.

2

Beyond Air Inc.

18

80

Israel

Moderate disease at enrollment

3: Moderate disease at enrollment

40

incidence of Serious Adverse Events

None

Not reported

[{"arm_notes": "", "treatment_id": 890, "treatment_name": "Nitric oxide gas", "treatment_type": "Gas inhalation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]